The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Takeaways in hepatocellular carcinoma at ASCO GI 2023
Stephen Lam Chan, MBBS, Chinese University of Hong Kong, Hong Kong, China, provides his highlights in the field of hepatocellular carcinoma (HCC) at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including trials assessing radiotherapy versus sorafenib, and trans arterial chemoembolization (TACE) post-surgery in patients with HCC. Dr Chan additionally highlights the Phase III SWOG 1815 trial (NCT03768414) of gemcitabine, cisplatin, and nab-paclitaxel in newly diagnosed, advanced biliary tract cancers. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
